[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:grade-1-follicular-lymphoma":3},{"name":4,"total":5,"trials":6,"biomarkers":22,"states":23},"Grade 1 Follicular Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",[11],"Phase 2","RECRUITING","2026-08-03T00:59:34.595768Z","2026-07-05T05:32:16.721320Z",{"nct_id":16,"title":17,"phases":18,"status":19,"updated_at":20,"content_modified":21},"NCT07731789","Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma",[11],"NOT_YET_RECRUITING","2026-08-03T01:02:43.946935Z","2026-07-30T01:46:14.455065Z",[],[]]